What the Best ASC Billing Companies Measure Every Month

The best ASC billing companies measure ten metrics every month — and the difference between a billing company that measures these ten and one that delivers a collections summary is the difference between a surgery center that grows and one that collects without knowing whether it collected what it was owed.

Most ASC billing companies report what arrived. The best ASC billing companies report what should have arrived, what did not, why, and what corrective action closes the gap before the next billing cycle opens. At a 4-OR surgery center performing 300 cases monthly, the gap between these two measurement disciplines represents $420,000 to $1,800,000 per 12 months in recoverable revenue that a collections summary accepts as a final number and a performance dashboard treats as a starting point.

These are the ten metrics the best ASC billing companies measure every month — and the benchmark each one must hit to qualify as a measurement discipline rather than a reporting exercise.

---

Metric 1 — Net Collection Rate by Procedure Category and by Payer

Benchmark: 94% or above overall; 96%+ on commercial; 91%+ on Medicare Advantage; 86%+ on Medicaid managed care — reported separately by orthopedic, spine, ophthalmologic, pain management, and general surgery procedure categories, and by each individual payer.

What separates best from adequate: adequate ASC billing companies report a single blended NCR. The best ASC billing companies report NCR broken out by procedure category and by payer — because a 94% blended NCR masking an 84% NCR on BCBS spine cases and a 97% NCR on UnitedHealthcare ophthalmologic cases requires two different corrective actions that a blended figure delays by 30 to 60 days. For how NCR measurement standards are shifting across ASC specialties, see Revenue Cycle Management in Healthcare.

---

Metric 2 — Implant Revenue Capture Rate by OR Room

Benchmark: 95% or above implant capture rate on every OR room for every procedure category; any OR room below 90% triggers an immediate charge capture workflow audit.

What separates best from adequate: adequate ASC billing companies capture implant revenue from physician-submitted implant logs. The best ASC billing companies run real-time OR log integration capturing implant use at case completion — eliminating the 10% to 18% capture failure rate that physician-submitted logs produce at high-volume orthopedic and spine ASCs. When OR 3 shows a 15% implant capture variance and OR 1 shows 2%, the best ASC billing companies identify OR 3’s charge capture workflow as the root cause within 30 days — not at the annual revenue review. For how implant revenue leakage compounds at scale, see ASC Implant Billing Revenue Leakage.

---

Metric 3 — Prior Authorization Denial Rate by Procedure Code and by Payer

Benchmark: below 5% overall PA denial rate; below 8% on any individual payer; below 10% on any individual high-revenue procedure code category — with month-over-month trend lines by payer and procedure code.

What separates best from adequate: adequate ASC billing companies track total PA denial volume. The best ASC billing companies track PA denial rate by procedure code and by payer — because a 7% overall PA denial rate masking a 16% PA denial rate on UnitedHealthcare spine cases and a 2% rate on commercial ophthalmologic cases requires a UnitedHealthcare-specific prior authorization workflow correction, not a general PA process review. For how payer-specific PA denial patterns are escalating in 2026, see Prior Auth Denial Trends 2026 and Payer-Specific Denial Patterns: How UHC and BCBS Are Denying Claims in 2026.

---

Metric 4 — Payer Variance Rate by Contracted Payer and Revenue Code

Benchmark: zero variance between contracted facility fee rate and actual payment on any payer and procedure code combination; any variance above $50 per claim triggers a contracted-rate dispute filing within 15 business days.

What separates best from adequate: adequate ASC billing companies review payments only when a denial is generated. The best ASC billing companies run payer variance detection on every remittance cycle — comparing contracted rates against actual payments by revenue code, CPT code, and payer on every claim processed. BCBS and UnitedHealthcare have documented patterns of applying internal payment edits that reduce facility fee payments on complex multi-procedure cases below contracted allowables without generating a denial. An ASC processing 200 surgical cases monthly with a 6% payer variance incidence rate and an average underpayment of $420 per case absorbs $604,800 per 12 months in silent underpayments that a collections summary accepts as correct payment.

---

Metric 5 — Days in AR by Case Type and by Payer

Benchmark: 35 days or below overall; 28 days or below on commercial; 42 days or below on Medicare Advantage; 48 days or below on Medicaid managed care — reported separately by orthopedic, spine, ophthalmologic, pain management, and general surgery case types.

What separates best from adequate: adequate ASC billing companies report a single blended Days in AR figure. The best ASC billing companies report Days in AR separated by case type and by payer — because spine cases aging past 50 days at UnitedHealthcare require a different corrective action than ophthalmologic cases aging past 50 days at a commercial payer. A blended Days in AR of 38 days masking a 62-day Days in AR on UnitedHealthcare spine cases delays the payer-specific corrective action by 30 to 45 days — compressing the appeal window on the aging spine claims simultaneously.

---

Metric 6 — 90-Plus Day AR Composition by Failure Mechanism

Benchmark: below 15% of total AR in the 90-plus day bucket; 85% or more of the 90-plus day bucket actively worked in the trailing 30 days; zero claims in the 90-plus day bucket without a documented failure mechanism classification.

What separates best from adequate: adequate ASC billing companies report 90-plus day AR as a percentage of total AR. The best ASC billing companies report 90-plus day AR broken out by failure mechanism — PA denial, bundling edit, implant passthrough, documentation correction, payer variance — because each failure mechanism has a different correction path, a different filing window deadline, and a different recovery rate. A 90-plus day AR bucket reported as 18% of total AR without failure mechanism segmentation is a write-off queue. The same 18% segmented by failure mechanism is a recovery workflow. For how 90-day AR composition reveals billing company performance gaps, see Medical Billing Company Red Flags.

---

Metric 7 — First-Pass Denial Rate by Denial Reason Code

Benchmark: below 5% overall first-pass denial rate; below 8% on any individual denial reason code category — with month-over-month trend lines and corrective action status for every denial category exceeding benchmark.

What separates best from adequate: adequate ASC billing companies report total denial volume. The best ASC billing companies report first-pass denial rate broken out by denial reason code — CO-4 (service not covered), CO-97 (NCCI bundling edit), CO-167 (diagnosis not covered), PR-1 (deductible) — because each reason code requires a different corrective action. A 7% first-pass denial rate with 4% driven by CO-97 bundling edits and 3% driven by CO-4 coverage denials requires an NCCI modifier resubmission protocol correction on the CO-97 category and a medical necessity appeal protocol on the CO-4 category — two completely different workflows that a blended denial rate triggers as one undifferentiated corrective action.

---

Metric 8 — Denial Overturn Rate on First Appeal by Denial Category

Benchmark: 65% or above of appealed denials overturned on first appeal; below 50% overturn rate on any individual denial category triggers an immediate appeal process audit for that category.

What separates best from adequate: adequate ASC billing companies track total appeals filed versus total appeals won. The best ASC billing companies track denial overturn rate by denial category — because a 65% overall overturn rate masking a 35% overturn rate on PA expiration denials and an 85% overturn rate on NCCI bundling edit appeals identifies a specific appeal process failure on PA expiration denials. The 35% overturn rate means the billing company is filing authorization expiration denials through the standard clinical appeal path rather than the corrected authorization request process — a routing failure that a denial category overturn rate surfaces and a blended overturn rate conceals.

---

Metric 9 — Implant Cost Passthrough Reconciliation Rate

Benchmark: 100% of implant cost passthrough claims reconciled against payer-specific contracted passthrough mechanisms within 30 days of payment receipt; zero open underpaid passthrough claims older than 45 days without active dispute status.

What separates best from adequate: adequate ASC billing companies apply a uniform implant passthrough billing approach across all payers. The best ASC billing companies maintain payer-specific implant passthrough mechanism maps — separately payable HCPCS thresholds for UnitedHealthcare, invoice-based passthrough with markup limits for Aetna, cost-to-charge ratio for BCBS on certain procedure categories — and reconcile every implant passthrough payment against the applicable payer-specific mechanism on every remittance cycle. A billing company applying UnitedHealthcare’s separately payable HCPCS threshold logic to an Aetna implant passthrough claim produces systematic underpayment on every Aetna implant claim — at $180 to $640 per spine instrumentation passthrough underpayment, the aggregate impact runs $86,400 to $307,200 per 12 months at 40 monthly spine cases.

---

Metric 10 — Yield EBITDA per OR per Month

Benchmark: practice-specific, established at contract execution against payer-specific ASC performance norms for the facility’s procedure mix, OR count, and geographic market — with month-over-month trend lines and upstream KPI attribution for any month showing below-benchmark Yield EBITDA.

What separates best from adequate: adequate ASC billing companies report monthly collections. The best ASC billing companies report Yield EBITDA per OR — net realized revenue per revenue-generating asset after billing costs, payer variances, write-offs, and contractual adjustments — with upstream KPI attribution identifying which of the nine metrics above is driving any below-benchmark Yield EBITDA per OR. When OR 2 shows declining Yield EBITDA despite stable case volume, the nine upstream metrics provide the diagnostic data to identify whether the compression is driven by implant capture failure, BCBS payer variance on multi-procedure cases, UnitedHealthcare PA denial escalation, or 90-day AR aging into permanent write-offs. Yield EBITDA per OR reported monthly with upstream attribution is growth intelligence. Yield EBITDA per OR inferred from a monthly collections summary is a hypothesis.

---

What to Do If Your ASC Billing Company Is Not Measuring These Ten Metrics

If your ASC billing company cannot produce all ten metrics in the format described above — segmented by procedure category, by payer, by denial reason code, and by failure mechanism — on the first business day of each month, it does not have the measurement infrastructure that ASC margin protection requires.

The corrective action is one of two paths: a measurement infrastructure improvement plan with a 90-day implementation timeline — or a billing company transition to MBC’s ASC billing infrastructure, which delivers all ten metrics as standard monthly KPIs before the next billing cycle opens.

---

How MBC Measures These Ten Metrics for ASC Clients

MBC’s ASC Billing Services delivers all ten metrics as standard monthly KPIs — not request-based reports or quarterly reviews. Our dedicated account manager populates every metric with your ASC’s actual OR and claims data, benchmarks every metric against payer-specific and procedure-specific ASC performance norms, flags every metric below benchmark with the specific denial root-cause or billing failure mechanism driving it, and presents every corrective action with a 30-day resolution timeline before the next billing cycle opens.

Our payer variance detection protocol runs on every remittance cycle — not exception-based. Our real-time OR log integration captures implant revenue at case completion — not from physician-submitted logs. Our Old AR Recovery unit classifies 90-plus day ASC claims by failure mechanism and works the recoverable portion within the applicable payer window as a standard service — not a project engagement. Our Denial Management infrastructure triages every denial by reason code within 24 hours — routing each category to the correct recovery path before the appeal window compresses.

With MBC’s 97% clean claim rate and proven 30% A/R reduction within 90 days, ASC clients measuring all ten metrics monthly recover an average of $420,000 to $1,800,000 per 12 months in revenue their previous billing vendor was measuring as a final collections number. For the broader ASC billing performance framework, see ASC Billing Challenges and ASC Billing and Coding Guidelines.

Practices completing MBC’s Complimentary 90-Day AR Diagnostic receive all ten metrics populated with their actual ASC claims data — with gap analysis, payer-specific benchmarks, and a 90-day correction roadmap before the next billing cycle closes.

Request Your Free Revenue Diagnostic — contact us at info@medicalbillersandcoders.com or call 888-357-3226.

Medical Billing Services | medicalbillersandcoders.com | 888-357-3226

---

Frequently Asked Questions

Q1. Why do the best ASC billing companies report NCR by procedure category and by payer rather than as a single blended figure?
A blended NCR conceals payer-specific and procedure-specific underperformance that requires different corrective actions. An 84% NCR on BCBS spine cases is driven by multi-procedure discounting logic that requires a payer contract-specific billing correction; a 97% NCR on UnitedHealthcare ophthalmologic cases confirms that workflow is functioning correctly. Treating both as a 94% blended NCR delays the BCBS spine corrective action by 30 to 60 days and compresses the appeal window on spine claims aging in the interim.

Q2. What is the revenue impact of not measuring implant capture rate by OR room?
An ASC not measuring implant capture rate by OR room absorbs a 10% to 18% charge capture failure rate on physician-submitted implant logs without identifying which OR room is generating the failure. At a 4-OR ASC performing 150 orthopedic and spine cases monthly, a 12% implant capture failure rate in OR 3 generates $259,200 to $648,000 per 12 months in unbilled implant costs — invisible on a denial report because no claim was submitted for the unbilled implant, and invisible on a collections summary because the revenue gap appears as a volume-versus-collections ratio rather than a line-item failure.

Q3. Why should denial overturn rate be tracked by denial category rather than as a total appeals-won percentage?
A total appeals-won percentage of 65% masking a 35% overturn rate on PA expiration denials indicates a structural appeal process routing failure — PA expiration denials are being filed through the standard clinical appeal path rather than the corrected authorization request process — that affects every PA expiration denial in the pipeline. Tracking overturn rate by denial category identifies the specific routing failure and corrects it before the appeal window expires on subsequent denials in the same category.

Q4. How does Yield EBITDA per OR differ from Net Collection Rate as a monthly performance metric?
NCR measures the percentage of collectible revenue that was collected — it does not account for billing costs, write-offs, payer variance adjustments, or implant passthrough reconciliation losses. Yield EBITDA per OR integrates all of these components into a single net realized revenue figure per revenue-generating asset — revealing whether OR 2 is producing lower net revenue than OR 1 despite similar case volumes, and attributing the per-OR margin gap to its specific upstream cause across the nine upstream metrics.

Q5. What corrective action applies when payer variance rate exceeds the $50 per claim threshold on a specific payer?
When payer variance on a specific payer exceeds $50 per claim, the corrective action is a contracted-rate dispute filing within 15 business days — not a standard denial appeal. The contracted-rate dispute process requires the ASC’s executed payer contract with the applicable procedure-category rate schedule, the remittance advice documenting the actual payment, and a formal dispute letter citing the specific contract provision the payer’s payment violates. A billing company filing payer variance events through the standard appeal process instead of the contracted-rate dispute process produces a procedurally incorrect filing that payers deny on process grounds — not on the merits of the underpayment claim.